Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ®)–Health Professional Version

OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER

SECTIONS

Changes to This Summary (02/07/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Overview

Added text to state that family history and mutation location within the BRCA1 or BRCA2 gene may contribute to the risk of cancer development among those with an inherited predisposition to ovarian cancer (cited Kuchenbaecker et al. as reference 1).

Description of the Evidence

Updated statistics with estimated new cases and deaths for 2018 (cited American Cancer Society as reference 1). Also added text to state that in 2014, the overall incidence rate for ovarian carcinoma among women aged 65 years and older was 41.9 cases per 100,000 women-years (cited Howlader et al. as reference 3).

Revised text to state that some women are at an increased risk because of an inherited mutation, with the magnitude of that risk influenced by the location of the specific mutation on the affected gene and a family history of cancer (cited Kuchenbaecker et al. as reference 5).

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Description of the Evidence

Next section >
About This PDQ Summary